Edition:
United Kingdom

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

15.60USD
23 Apr 2018
Change (% chg)

-- (--)
Prev Close
$15.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
81,602
52-wk High
$24.00
52-wk Low
$5.90

Chart for

About

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood... (more)

Overall

Beta: --
Market Cap(Mil.): $387.63
Shares Outstanding(Mil.): 27.69
Dividend: --
Yield (%): --

Financials

  KURA.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.53 -- --
ROI: -46.24 1.58 14.38
ROE: -52.12 2.41 16.07

BRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And Company​

* KURA ONCOLOGY INC - ‍ON MARCH 12, 2018, CO ENTERED INTO AN AMENDED AND RESTATED SALES AGREEMENT WITH COWEN AND COMPANY, LLC - SEC FILING​

12 Mar 2018

BRIEF-Kura Oncology Provides Regulatory Update On Tipifarnib

* KURA ONCOLOGY PROVIDES REGULATORY UPDATE ON TIPIFARNIB AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

12 Mar 2018

BRIEF-Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​

* Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​ Source text:(http://bit.ly/2yNnKBA) Further company coverage:

09 Nov 2017

BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co

* Kura Oncology Inc - on Nov 9, 2017, co entered into amendment to its sales agreement, dated January 27, 2017 with Cowen and Company LLC ‍​-SEC filing

09 Nov 2017

BRIEF-Kura Oncology reports third quarter 2017 financial results

* Kura Oncology reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

BRIEF-KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL

* KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE

27 Oct 2017

Earnings vs. Estimates